title: Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.
abstract: To compare the prevalence of extrapyramidal syndrome (EPS) between the first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), the co-prescribing rate of anti-Parkinson drugs (APDs) of each antipsychotic drug was analyzed using population database. Fourteen antipsychotics had been prescribed during the 5-year study period. Among the SGAs, quetiapine had the lowest crude co-prescribing rate of APDs (27.09%), whereas risperidone had the highest rate (66.50%). Among the FGAs, thioridazine and loxapine had the lowest (60.99%) and highest rates (96.35%), respectively. The rankings of the co-prescribing rate of APDs among antipsychotics, in increasing order, were quetiapine, clozapine, olanzapine, thioridazine, zotepine, chlorpromazine, risperidone, sulpiride, clotiapine, flupentixol, haloperidol, zuclopentixol, trifluoperazine, and loxapine. The results indicate that the risk of EPS appears to be lower in SGAs than in FGAs; however, the considerably high rate of EPS in some of the newer generation of antipsychotics warrants clinical attention.
authors.affiliation: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: S-Y
authors.initials: SY
authors.lastname: Yang
authors.forename: Y-H
authors.initials: YH
authors.lastname: Kao Yang
authors.forename: M-Y
authors.initials: MY
authors.lastname: Chong
authors.forename: Y-H
authors.initials: YH
authors.lastname: Yang
authors.forename: W-H
authors.initials: WH
authors.lastname: Chang
authors.forename: C-S
authors.initials: CS
authors.lastname: Lai
mesh_terms: D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004363:Drug Utilization; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009313:National Health Programs / Q000706:statistics & numerical data; D011153:Population; D012306:Risk; D012559:Schizophrenia / Q000150:complications*; D013624:Taiwan / Q000453:epidemiology
chemical_list: D018726:Anti-Dyskinesia Agents; D000928:Antidepressive Agents; D018692:Antimanic Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives